Celera Genomics Signs Genset to Database Subscription Deal
Rockville, MD, USA and Paris, France - January 09, 2001
Celera Genomics (NYSE: CRA), an Applera Corporation business, and Genset S.A. (Nouveau Marché: GENSET, Nasdaq: GENXY), announced today that Genset has signed a multi-year subscription agreement to Celera’s databases. Genset researchers will use Celera’s integrated database products, bioinformatics systems, and other discovery tools in conducting their genomics research and will access Celera’s products through the web-based Celera Discovery System™. Financial terms of the agreement were not disclosed.
“This agreement with Genset, one of the leading international genomic companies, is an example of the ways that Celera intends to build the capabilities necessary to participate in the drug discovery and development process,” said J. Craig Venter, Ph.D., Celera’s president and chief scientific officer. “Celera continues to generate genomic and other biological data from various organisms and to develop the tools and software needed to mine this large volume of data, thus creating a valuable resource for the scientific community.”
André Pernet, Ph.D., Genset’s president and chief executive officer commented, “The quantity and quality of the data in Celera’s databases should enable us to accelerate and reduce the costs of our genomics research. This will allow us to focus our time and resources on adding functional and medical information to genomics data. We believe the tools and experience we have developed over the past years have prepared us to fully exploit this data.”
The Celera Discovery System is a fully integrated, web-based discovery system that allows users to leverage Celera’s computational tools, super-computing power, and the genomic and biological data to advance the discovery process for researchers worldwide.
Genset is a genomics company committed to generating a pipeline of drug candidates for the treatment of central nervous system and metabolic disorders. Genset's integrated technology platform combined with ongoing genomic association studies will continue to identify and characterize potential drug targets and drug response markers for these disorders. By relying upon the expertise accumulated through various alliances with pharmaceutical partners and its portfolio of genomic patents, Genset now intends to pursue and validate novel drug targets and candidates for its own account. Genset has already discovered a lead protein candidate in the obesity field named Famoxin and is pursuing its research with a view to developing Famoxin into a drug. News releases by Genset are available on the company's web site at www.genxy.com
Applera Corporation, formerly PE Corporation, comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. Celera has developed three business units: the On-line Information Business, Discovery Sciences, and Discovery Services, all of which build upon Celera’s generation, integration, and analysis of biological information. Celera intends to enable therapeutic discoveries both through its own application of its scientific capabilities and in partnership with pharmaceutical and biotechnology companies. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins in order to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at www.applera.com or by telephoning 800.762.6923.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics' businesses include but are not limited to (1) operating losses to date; (2) a unique and expanding business plan; (3) dependence on the final assembly and annotation of the human genome; (4) uncertainty of revenue growth; (5) unproven use of genomics information to develop products; (6) intense competition in the evolving genomics industry; (7) dependence on customers in and subject to the risks of the pharmaceutical and biotechnology industries; (8) heavy reliance on strategic relationship with the Applied Biosystems Group; (9) lengthy sales cycle; (10) dependence on the unique expertise of its scientific and management staff; (11) uncertainty of patent, copyright, and intellectual property protection; (12) dependence on computer hardware, software, and internet applications; (13) access to biological materials; (14) legal, ethical, and social issues affecting demand for products; (15) disruptions caused by rapid growth of the business; (16) government regulation of its products and services; (17) risks of future acquisitions; (18) uncertainty of outcome of stockholder litigation; and (19) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission.
Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.